Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons

Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%

OBI forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date

The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders

OBI’s BOD resolved employees and amount granted for the first issuance of RSU and authorized the decision of record date to the Chairman

The Company's Board of Directors approved the amendment of 2022 Restricted Stock Awards Issuance Rules

Announcement of the Consolidated Financial Statements for the second quarter of 2022 were approved by the Board of Directors

Announcement on behalf of subsidiary, Obigen Pharma Inc., that BOD resolved the Term Sheet for licensing of OBI-858 in China

SUPPLEMENTARY STATEMENTS ON NEWS ARTICLE

The Company announces discontinuation of the Phase II Study of OBI-888